JP6285461B2 - 二環式ピリミジン化合物 - Google Patents

二環式ピリミジン化合物 Download PDF

Info

Publication number
JP6285461B2
JP6285461B2 JP2015552726A JP2015552726A JP6285461B2 JP 6285461 B2 JP6285461 B2 JP 6285461B2 JP 2015552726 A JP2015552726 A JP 2015552726A JP 2015552726 A JP2015552726 A JP 2015552726A JP 6285461 B2 JP6285461 B2 JP 6285461B2
Authority
JP
Japan
Prior art keywords
mmol
dihydro
ylamino
inden
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015552726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505010A5 (OSRAM
JP2016505010A (ja
Inventor
ボーチャンプ，トーマス，ジェームス
ダオ，イエン
ジョーンズ，スペンサー，ブライアン
ノーマン，ブライアン，ハースト
フェイファー，ランス，アレン
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2016505010A publication Critical patent/JP2016505010A/ja
Publication of JP2016505010A5 publication Critical patent/JP2016505010A5/ja
Application granted granted Critical
Publication of JP6285461B2 publication Critical patent/JP6285461B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
JP2015552726A 2013-01-11 2014-01-07 二環式ピリミジン化合物 Expired - Fee Related JP6285461B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751363P 2013-01-11 2013-01-11
US61/751,363 2013-01-11
US201361777201P 2013-03-12 2013-03-12
US61/777,201 2013-03-12
PCT/US2014/010400 WO2014110000A1 (en) 2013-01-11 2014-01-07 Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain

Publications (3)

Publication Number Publication Date
JP2016505010A JP2016505010A (ja) 2016-02-18
JP2016505010A5 JP2016505010A5 (OSRAM) 2017-02-16
JP6285461B2 true JP6285461B2 (ja) 2018-02-28

Family

ID=50031555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552726A Expired - Fee Related JP6285461B2 (ja) 2013-01-11 2014-01-07 二環式ピリミジン化合物

Country Status (13)

Country Link
US (1) US8969555B2 (OSRAM)
EP (1) EP2943494B1 (OSRAM)
JP (1) JP6285461B2 (OSRAM)
KR (1) KR101757997B1 (OSRAM)
CN (1) CN104903327B (OSRAM)
AU (1) AU2014205642B2 (OSRAM)
BR (1) BR112015015812A2 (OSRAM)
CA (1) CA2893253C (OSRAM)
EA (1) EA025106B1 (OSRAM)
ES (1) ES2636248T3 (OSRAM)
MX (1) MX2015008971A (OSRAM)
TW (1) TWI499591B (OSRAM)
WO (1) WO2014110000A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
HUE055213T2 (hu) 2013-11-22 2021-11-29 Sabre Therapeutics Llc Autotaxin inhibitor vegyületek
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CA2986759C (en) 2015-05-27 2025-06-17 Sabre Therapeutics Llc AUTOTAXIN INHIBITORS AND THEIR USES
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
CN110526929A (zh) * 2018-05-24 2019-12-03 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
EP3823620A4 (en) * 2018-07-16 2022-09-14 The Scripps Research Institute OPIOID HAPTENES, CONJUGATES, VACCINES AND METHODS OF GENERATING ANTIBODIES
KR102629358B1 (ko) * 2019-02-01 2024-01-24 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 피롤로피리미딘 유도체 및 그의 용도
CN112457296B (zh) * 2019-09-06 2023-11-07 武汉人福创新药物研发中心有限公司 嘧啶类化合物及其制备方法
CA3150700A1 (en) * 2019-09-17 2021-03-25 Renato T. Skerlj IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2021088957A1 (zh) * 2019-11-07 2021-05-14 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
WO2021115375A1 (zh) * 2019-12-11 2021-06-17 四川海思科制药有限公司 含氮杂环类自分泌运动因子抑制剂及其组合物和用途
CN113943296B (zh) * 2020-07-16 2025-07-04 武汉人福创新药物研发中心有限公司 吡咯并嘧啶衍生物及其应用
CN113943295B (zh) * 2020-07-16 2025-08-12 武汉人福创新药物研发中心有限公司 吡咯并嘧啶类化合物及其用途
CN113999236B (zh) * 2020-07-28 2025-06-10 武汉人福创新药物研发中心有限公司 含氮杂环化合物的盐及其盐的固体形式、药物组合物和用途
WO2022022569A1 (zh) * 2020-07-28 2022-02-03 武汉人福创新药物研发中心有限公司 含氮杂环化合物的固体形式及其药物组合物和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1230225A2 (en) * 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
WO2003104230A1 (ja) 2002-06-07 2003-12-18 協和醱酵工業株式会社 二環性ピリミジン誘導体
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
EP1885369B1 (en) * 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
EP2352732B1 (en) * 2008-12-01 2013-02-20 Merck Patent GmbH 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
ES2646834T3 (es) 2010-08-20 2017-12-18 Amira Pharmaceuticals, Inc. Inhibidores de autotaxina y usos de los mismos
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
US9273011B2 (en) * 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物

Also Published As

Publication number Publication date
EA025106B1 (ru) 2016-11-30
TW201437209A (zh) 2014-10-01
US8969555B2 (en) 2015-03-03
MX2015008971A (es) 2015-09-28
EA201591098A1 (ru) 2015-11-30
ES2636248T3 (es) 2017-10-05
CA2893253A1 (en) 2014-07-17
EP2943494A1 (en) 2015-11-18
JP2016505010A (ja) 2016-02-18
TWI499591B (zh) 2015-09-11
KR101757997B1 (ko) 2017-07-13
BR112015015812A2 (pt) 2017-07-11
CA2893253C (en) 2017-11-28
CN104903327A (zh) 2015-09-09
US20140200231A1 (en) 2014-07-17
WO2014110000A1 (en) 2014-07-17
AU2014205642B2 (en) 2016-02-25
KR20150092761A (ko) 2015-08-13
EP2943494B1 (en) 2017-02-22
CN104903327B (zh) 2016-09-07
AU2014205642A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
JP6285461B2 (ja) 二環式ピリミジン化合物
JP6133491B2 (ja) ジヒドロピリドピリミジン化合物
JP6163248B2 (ja) イミダゾピリジン化合物
ES2911428T3 (es) Inhibidores de STAT3
CA2909442A1 (en) N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
JP2018517731A (ja) Ｎｒｆ２レギュレーター
US5741794A (en) Heterocyclic sulfonamide derivatives as antagonists of PAF and angiotensin II
JP2015507016A (ja) ３環式インドール誘導体有用内皮リパーゼ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180201

R150 Certificate of patent or registration of utility model

Ref document number: 6285461

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees